OTC Markets OTCPK - Delayed Quote USD

Clinuvel Pharmaceuticals Limited (CLVLF)

Compare
9.28 0.00 (0.00%)
At close: September 26 at 4:00 PM EDT
Loading Chart for CLVLF
DELL
  • Previous Close 0.00
  • Open 11.55
  • Bid 9.43 x 39400
  • Ask 10.58 x 34100
  • Day's Range 11.55 - 11.55
  • 52 Week Range 8.57 - 11.55
  • Volume 3,570
  • Avg. Volume 103
  • Market Cap (intraday) 488.481M
  • Beta (5Y Monthly) 0.92
  • PE Ratio (TTM) 19.33
  • EPS (TTM) 0.48
  • Earnings Date Aug 28, 2024
  • Forward Dividend & Yield 0.03 (0.37%)
  • Ex-Dividend Date Sep 5, 2024
  • 1y Target Est --

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRéNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

www.clinuvel.com

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: CLVLF

View More

Performance Overview: CLVLF

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CLVLF
11.42%
S&P/ASX 200 [XJO]
8.19%

1-Year Return

CLVLF
1.07%
S&P/ASX 200 [XJO]
16.81%

3-Year Return

CLVLF
68.82%
S&P/ASX 200 [XJO]
11.21%

5-Year Return

CLVLF
47.31%
S&P/ASX 200 [XJO]
22.28%

Compare To: CLVLF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CLVLF

View More

Valuation Measures

Annual
As of 9/26/2024
  • Market Cap

    488.48M

  • Enterprise Value

    363.66M

  • Trailing P/E

    19.25

  • Forward P/E

    18.98

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.78

  • Price/Book (mrq)

    3.32

  • Enterprise Value/Revenue

    6.05

  • Enterprise Value/EBITDA

    9.47

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    40.41%

  • Return on Assets (ttm)

    14.29%

  • Return on Equity (ttm)

    19.39%

  • Revenue (ttm)

    88.18M

  • Net Income Avi to Common (ttm)

    35.64M

  • Diluted EPS (ttm)

    0.48

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    183.87M

  • Total Debt/Equity (mrq)

    0.43%

  • Levered Free Cash Flow (ttm)

    23.45M

Company Insights: CLVLF

People Also Watch